GSK plc (NYSE:GSK) Receives $40.58 Consensus Target Price from Analysts

Shares of GSK plc (NYSE:GSK - Get Free Report) have been assigned a consensus recommendation of "Hold" from the twelve brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and three have issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $40.58.

Several equities research analysts have recently issued reports on GSK shares. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. Hsbc Global Res raised GSK to a "strong sell" rating in a report on Monday, April 28th. BNP Paribas began coverage on GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target for the company. Finally, Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company.

Institutional Trading of GSK

Institutional investors have recently made changes to their positions in the business. Indiana Trust & Investment Management Co raised its position in GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Crews Bank & Trust bought a new position in GSK in the 4th quarter worth approximately $26,000. HHM Wealth Advisors LLC raised its position in shares of GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares during the last quarter. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 522 shares during the period. Finally, Costello Asset Management INC acquired a new stake in shares of GSK during the 1st quarter worth approximately $31,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Down 0.3%

NYSE:GSK traded down $0.10 during trading hours on Monday, reaching $36.25. The company's stock had a trading volume of 7,082,097 shares, compared to its average volume of 4,809,558. The business's 50-day moving average is $37.56 and its 200-day moving average is $35.97. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK has a one year low of $31.72 and a one year high of $45.93. The company has a market cap of $74.79 billion, a price-to-earnings ratio of 22.80, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The company had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same quarter last year, the firm posted $0.43 earnings per share. The company's quarterly revenue was up 2.1% compared to the same quarter last year. Equities research analysts predict that GSK will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be issued a $0.4216 dividend. This represents a $1.69 annualized dividend and a yield of 4.65%. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is 86.60%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.